Journal article
Phase II Study of Troxacitabine (BCH-4556) in Patients with Advanced Non-Small-Cell Lung Cancer
Abstract
Troxacitabine. a promising new L-nucleoside, inhibits DNA polymerase and leads to complete DNA chain termination. The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) conducted a phase II study to assess the efficacy and toxicity of troxacitabine in untreated patients with advanced non-small-cell lung cancer (NSCLC). Previously untreated patients were eligible if they had inoperable stage IIIB or IV NSCLC, ECOG PS ≤ 2, …
Authors
Dent SF; Arnold A; Stewart DJ; Gertler S; Ayoub J; Batist G; Goss G; Nevile A; Soulieres D; Jolivet J
Journal
Lung, Vol. 183, No. 4, pp. 265–272
Publisher
Springer Nature
Publication Date
August 2005
DOI
10.1007/s00408-004-2539-7
ISSN
0341-2040